Chemokine CX3CL1 has potential anti-fibrosis effect in mouse liver fibrosis

doi:10.16352/j.issn.1001-6325.2023.12.1792

Abstract

Abstract: Objective To explore the effect and mechanism of chemokine CX3CL1 on mouse liver fibrosis model. Methods C57BL/6 mice were randomly divided into CCl-4 model group and normal control group with 8 animals in each group. The model group was injected with 10% CCl-4 intra peritoneally for 6 weeks. After 6 weeks, the mice were sacrificed, and the pathological changes of the mouse liver were observed by HE staining. The level of CX3CL1 in peripheral blood of the mice was measured, and the expression level of CX3CL1 mRNA in the liver tissue of the mice was detected. In addition, in order to explore the mechanism of CX3CL1, the level of IFN-γ in mouse serum was detected as well. Results After the 6-week modeling, the liver pathology microscopy showed a successful modeling of liver fibrosis. The serum CX3CL1 level and liver tissue CX3CL1 expression in the model group were found to be significantly up-regulated, which suggested a potential impact on the pathogenesis of liver fibrosis. In addition, the level of IFN-γ in the serum of mice in the model group increased significantly. Conclusions CX3CL1 is related to liver fibrosis in mice, and its mechanism might be explained by promoting the production of IFN-γ so to prevent liver fibrosis.

Key words: chemokine, CX3CL1, liver fibrosis, interferon-γ

CLC Number:

R575

CHENG Qi, LI Ning, YU Kangkang, SHI Guangfeng. Chemokine CX3CL1 has potential anti-fibrosis effect in mouse liver fibrosis[J]. Basic & Clinical Medicine, 2023, 43(12): 1792-1795.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.12.1792

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I12/1792

References 13

[1]	Bataller R, Brenner DA. Liver fibrosis[J]. J Clin Invest, 2005, 115:209-218.
[2]	Friedman SL. Liver fibrosis-from bench to bedside[J]. J Hepatol, 2003,38(Suppl 1):S38-S53.
[3]	Fraticelli P, Sironi M, Bianchi G, et al. Fractalkine(CX3CL1) as an amplification circuit of polarized Th1 responses[J]. J Clin Invest, 2001,107: 1173-1181.
[4]	Vitale S, Cambien B, Karimdjee BF,et al.Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer[J]. Gut, 2007, 56:365-372.
[5]	Ohta M, Tanaka F, Yamaguchi H, et al. The high expression of fractalkine results in a better prognosis for colorectal cancer patients[J]. Int J Oncol, 2005, 26:41-47.
[6]	Tomonori Aoyama, Sayaka Inokuchi, David A, et al.CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice[J]. Hepatology, 2010,52:1390-1400.
[7]	Isse K, Harada K, Zen Y, et al. Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts[J]. Hepatology, 2005, 41:506-516.
[8]	李少华,邱玲,程歆琦等,腹腔注射低浓度四氯化碳建立小鼠肝纤维化模型. 基础医学与临床[J],2014,34:1694-1695.
[9]	程琦,施光峰. 趋化因子CX3CL1及其受体在肝脏炎症和纤维化中的作用. 中国肝脏病杂志(电子版)[J], 2012,4: 55-58.
[10]	Safadi R, Friedman SL. Hepatic fibrosis-role of hepatic stellate cell activation[J]. MedGenMed, 2002, 4: 27-27.
[11]	Karlin KR,Zimmermann HW,Roderburg C,et al.The fractalkine receptor CX3CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrat-ing hepatic monocytes[J].Hepatology,2010,52:1769-1782.
[12]	David A, La J. Molecular pathogenesis of liver fibrosis[J]. Trans Am Clin Climatol Assoc. 2009,120:361-368.
[13]	Wells RG, Kruglov E, Dranoff JA. Autocrine release of TGF-beta by portal fibroblasts regulates cell growth[J]. FEBS Lett, 2004,559:107-110.